share_log

Panbela Therapeutics | 8-K: Current report

SEC announcement ·  Mar 27 04:16
Summary by Futu AI
On March 26, 2024, Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, issued a press release announcing its financial results for the year ended December 31, 2023. The announcement, filed with the SEC on Form 8-K, highlighted the company's business updates, including clinical trial progress and financial milestones. Panbela reported a net loss of $6.5 million, or $65.90 per diluted share, for the fourth quarter of 2023, compared to a net loss of $4.7 million, or $344.61 per diluted share, for the same period in 2022. Research and development expenses increased to $6.1 million from $3.5 million year-over-year. The company also completed a public offering on January 31, 2024, raising approximately $9 million. Panbela's pipeline includes clinical trials focusing on various cancers and diabetes, with its lead assets being Ivospemin (SBP-101) and Flynpovi. The company's ASPIRE trial for untreated metastatic pancreatic ductal adenocarcinoma has exceeded 50% enrollment, with full enrollment expected by Q1 2025. Panbela's stock is listed on The Nasdaq Stock Market LLC under the symbol 'PBLA'.
On March 26, 2024, Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, issued a press release announcing its financial results for the year ended December 31, 2023. The announcement, filed with the SEC on Form 8-K, highlighted the company's business updates, including clinical trial progress and financial milestones. Panbela reported a net loss of $6.5 million, or $65.90 per diluted share, for the fourth quarter of 2023, compared to a net loss of $4.7 million, or $344.61 per diluted share, for the same period in 2022. Research and development expenses increased to $6.1 million from $3.5 million year-over-year. The company also completed a public offering on January 31, 2024, raising approximately $9 million. Panbela's pipeline includes clinical trials focusing on various cancers and diabetes, with its lead assets being Ivospemin (SBP-101) and Flynpovi. The company's ASPIRE trial for untreated metastatic pancreatic ductal adenocarcinoma has exceeded 50% enrollment, with full enrollment expected by Q1 2025. Panbela's stock is listed on The Nasdaq Stock Market LLC under the symbol 'PBLA'.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.